Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced the initiation of the phase II HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE